Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Octanedioate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 5/20 | 0.92 |
| ▸ | LMNA | P02545 | 4/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.92 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.92 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.71 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.71 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.71 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.69 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.69 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.69 |
| ▸ | PPARG | P37231 | 6/20 | 0.67 |
| ▸ | PPARD | Q03181 | 6/20 | 0.67 |
| ▸ | PPARA | Q07869 | 6/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | TLR2 | O60603 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimelic Acid SCHEMBL100415 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Sebacic Acid SCHEMBL20594219 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Succinic Acid SCHEMBL28346539 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Azelaic Acid SCHEMBL10456758 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Sebacic Acid SCHEMBL8405057 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Succinic Acid SCHEMBL28059863 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Octanedioate SCHEMBL5800699 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Octanedioate SCHEMBL28812368 | 0.96 | TSHR (0.86) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Pimelic Acid SCHEMBL28069641 | 0.96 | TSHR (0.86) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Octanedioate SCHEMBL28269347 | 0.96 | TSHR (0.86) | TSHRLMNANFKB1PMP22SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115701464-B | Super-hydrophobic finishing agent and preparation method and application thereof | 江苏金太阳纺织科技股份有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-115418148-A | Organic reversible thermochromic exterior wall coating and preparation method thereof | 中机铸材科技（福建）有限公司 | 2022-12-02 | — | — | CN | claimed |
| CN-113981713-A | Method for dyeing real silk fabric by using natural dye | 达利(中国)有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-9725466-B2 | Rifaximin derivative and uses thereof | Salix Pharmaceuticals, Ltd (US) | 2017-08-08 | — | — | US | claimed |
| US-20160257700-A1 | RIFAXIMIN DERIVATIVE AND USES THEREOF | BAUSCH HEALTH US, LLC | 2016-09-08 | — | — | US | claimed |
| CN-117881401-A | NLRP3 modulators | 祖玛珍生物科学有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117858870-A | Preparation of P2X3 antagonists | 葛兰素史密斯克莱知识产权(第3号)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117597345-A | Heterocyclic derivatives as CaMKK2 inhibitors | 百时美施贵宝公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-113981713-B | Method for dyeing real silk fabric by adopting natural dye | 达利(中国)有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-117241797-A | Method for treating prostate cancer | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-111566089-B | IRE1 small molecule inhibitors | 康奈尔大学 | 2023-11-17 | — | — | CN | disclosed |
| CN-116472292-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-5504104-A | TREATING INFECTIONS OR DISEASES CAUSED BY RETROVIRUSES, SUCH AS HIV AND AIDS | WARNER-LAMBERT COMPANY (US) | 1996-04-02 | — | — | US | disclosed |
| WO-1996007648-A1 | 2-SUBSTITUTED-4H-3,1-BENZOXAZIN-4-ONES AND BENZTHIAZIN-4-ONES AS INHIBITORS OF COMPLEMENT Clr PROTEASE FOR THE TREATMENT OF INFLAMMATORY PROCESSES | WARNER-LAMBERT COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
| WO-1995014013-A1 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995014012-A1 | 5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995014011-A2 | 5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995014014-A2 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |
| EP-0359796-A1 | THERMOSETTING COMPOSITION FROM MALEIMIDE, OLEFINIC MONOMER AND UNSATURATED POLYESTER. | ARISTECH CHEMICAL CORP (US) | 1990-03-28 | — | — | EP | disclosed |
| WO-1989008670-A1 | THERMOSETTING COMPOSITION FROM MALEIMIDE, OLEFINIC MONOMER AND UNSATURATED POLYESTER | ARISTECH CHEMICAL CORPORATION (US) | 1989-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257700-A1 | RIFAXIMIN DERIVATIVE AND USES THEREOF | CUTA, SSB, MRPL21 | SLC6A2 1390/4885TSHR 3262/4885LMNA 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.